JP2019530692A5 - - Google Patents

Download PDF

Info

Publication number
JP2019530692A5
JP2019530692A5 JP2019517045A JP2019517045A JP2019530692A5 JP 2019530692 A5 JP2019530692 A5 JP 2019530692A5 JP 2019517045 A JP2019517045 A JP 2019517045A JP 2019517045 A JP2019517045 A JP 2019517045A JP 2019530692 A5 JP2019530692 A5 JP 2019530692A5
Authority
JP
Japan
Prior art keywords
substituted
pharmaceutically acceptable
alkyl
compound
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019517045A
Other languages
English (en)
Other versions
JP2019530692A (ja
JP7274415B2 (ja
JPWO2018060317A5 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/074600 external-priority patent/WO2018060317A1/en
Publication of JP2019530692A publication Critical patent/JP2019530692A/ja
Publication of JP2019530692A5 publication Critical patent/JP2019530692A5/ja
Publication of JPWO2018060317A5 publication Critical patent/JPWO2018060317A5/ja
Application granted granted Critical
Publication of JP7274415B2 publication Critical patent/JP7274415B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (7)

  1. 式(I)
    Figure 2019530692

    [式中、
    1Aは、水素、置換または非置換のC1〜3アルキル、複素環、または置換もしくは非置換のホスホロアミデートから選択され、
    1Bは、水素、置換または非置換のC1〜3アルキル、複素環、または置換もしくは非置換のホスホロアミデートから選択され、
    ただし、R1AおよびR1Bの両方ともが水素ではないことを条件とし、
    は、任意選択的にヒドロキシル基で置換されている、C1〜8アルキルである]
    の化合物、またはその薬学的に許容可能な塩、溶媒和物もしくは多形体。
  2. 1Aおよび/またはR1Bが、置換または非置換のホスホロアミデートであり、Rが、C1〜6アルキル、好ましくはヒドロキシル基で置換されている 1〜6 アルキルである、請求項1に記載の化合物。
  3. 1Aおよび/またはR1Bがメチルであり、Rがヒドロキシル基で置換されているC−アルキルである、請求項1に記載の化合物。
  4. 請求項1〜3のいずれか一項に記載の式(I)の化合物、またはその薬学的に許容可能な塩、溶媒和物もしくは多形体を、1種または複数種の薬学的に許容可能な添加剤、希釈剤または担体とともに含む医薬組成物。
  5. 薬剤として使用するための、請求項1〜3のいずれか一項に記載の式(I)の化合物、もしくはその薬学的に許容可能な塩、溶媒和物もしくは多形体、または請求項4に記載の、前記式(I)の化合物、もしくはその薬学的に許容可能な塩、溶媒和物もしくは多形体を含む医薬組成物。
  6. インターフェロンの誘導が関与する障害の処置に使用するための、請求項1〜3のいずれか一項に記載の式(I)の化合物、もしくはその薬学的に許容可能な塩、溶媒和物もしくは多形体、または請求項4に記載の、前記式(I)の化合物、もしくはその薬学的に許容可能な塩、溶媒和物もしくは多形体を含む医薬組成物。
  7. 以下からなる群より選択される化合物:
    Figure 2019530692
JP2019517045A 2016-09-29 2017-09-28 ウイルス感染症および他の疾患を処置するためのピリミジンプロドラッグ Active JP7274415B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16191568 2016-09-29
EP16191568.1 2016-09-29
PCT/EP2017/074600 WO2018060317A1 (en) 2016-09-29 2017-09-28 Pyrimidine prodrugs for the treatment of viral infections and further diseases

Publications (4)

Publication Number Publication Date
JP2019530692A JP2019530692A (ja) 2019-10-24
JP2019530692A5 true JP2019530692A5 (ja) 2020-11-12
JPWO2018060317A5 JPWO2018060317A5 (ja) 2022-09-05
JP7274415B2 JP7274415B2 (ja) 2023-05-16

Family

ID=57047069

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019517045A Active JP7274415B2 (ja) 2016-09-29 2017-09-28 ウイルス感染症および他の疾患を処置するためのピリミジンプロドラッグ

Country Status (12)

Country Link
US (2) US10968184B2 (ja)
EP (1) EP3519406B1 (ja)
JP (1) JP7274415B2 (ja)
KR (1) KR102450287B1 (ja)
CN (1) CN109790154B (ja)
AU (1) AU2017335205B2 (ja)
CA (1) CA3037989A1 (ja)
EA (1) EA038646B1 (ja)
ES (1) ES2912945T3 (ja)
MA (1) MA46340A (ja)
SG (1) SG10202010317VA (ja)
WO (1) WO2018060317A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020255035A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyrimidine derivatives

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2610889B2 (ja) 1987-09-03 1997-05-14 日本臓器製薬株式会社 新規架橋アデニン誘導体
AU698419B2 (en) 1996-07-03 1998-10-29 Dainippon Sumitomo Pharma Co., Ltd. A novel purine derivative
HUP9903965A3 (en) 1996-08-28 2002-02-28 Pfizer Substituted 6,5-hetero-bicyclic derivatives
AU733316B2 (en) 1996-10-04 2001-05-10 Kyorin Pharmaceutical Co. Ltd. Pyrazolopyridylpyridazinone derivatives and process for preparing the same
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
WO1999028321A1 (fr) 1997-11-28 1999-06-10 Sumitomo Pharmaceuticals Company, Limited Nouveaux composes heterocycliques
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
BR9908004A (pt) 1998-02-17 2001-12-18 Tularik Inc Composto, composição e método para prevençãoou supressão de uma infecção viral
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP4342007B2 (ja) 1998-08-10 2009-10-14 大日本住友製薬株式会社 キナゾリン誘導体
JP4315300B2 (ja) 1998-08-10 2009-08-19 大日本住友製薬株式会社 新規なキナゾリン誘導体
US6458798B1 (en) 1998-08-27 2002-10-01 Sumitomo Pharmaceuticals Company, Limited Bicyclic pyrimidine compounds and therapeutic use thereof
WO2000048606A1 (en) * 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
US6503908B1 (en) 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
AU2002364211A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
JPWO2003104230A1 (ja) 2002-06-07 2005-10-06 協和醗酵工業株式会社 二環性ピリミジン誘導体
MXPA05003193A (es) 2002-09-27 2005-06-08 Sumitomo Pharma Compuesto de adenina novedoso y uso del mismo.
US8455458B2 (en) 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
JP2007524615A (ja) 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター(tlr)アンタゴニスト
ATE465742T1 (de) 2003-09-05 2010-05-15 Anadys Pharmaceuticals Inc Tlr7-liganden zur behandlung von hepatitis c
BRPI0509258A8 (pt) 2004-03-26 2019-01-22 Astrazeneca Ab composto de 8-oxoadenina 9-substituída
US20070225303A1 (en) 2004-03-26 2007-09-27 Haruhisa Ogita 8-Oxoadenine Compound
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
EP1797050B1 (en) 2004-08-10 2013-10-23 Janssen Pharmaceutica NV Hiv inhibiting 1.2.4-triazin-6-one derivates
MX2007001713A (es) * 2004-08-11 2007-07-13 Donald L Barbeau Compuestos farmaceuticos no cardiotoxicos.
KR100915481B1 (ko) 2004-11-09 2009-09-03 에프. 호프만-라 로슈 아게 아미노퀴나졸린 화합물
US7498409B2 (en) 2005-03-24 2009-03-03 Schering Corporation Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists
CN101203519A (zh) 2005-05-04 2008-06-18 辉瑞有限公司 用于治疗癌症和病毒感染如丙型肝炎的用作Toll样受体调节剂的2-酰氨基-6-氨基-8-氧代嘌呤衍生物
TW200716631A (en) 2005-05-12 2007-05-01 Tibotec Pharm Ltd Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
US7994360B2 (en) 2005-05-16 2011-08-09 Xtl Biopharmaceuticals Ltd. Benzofuran compounds
TWI404537B (zh) 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
EP1924564B1 (en) 2005-09-01 2016-11-09 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
US20090192153A1 (en) 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
WO2007056208A2 (en) 2005-11-02 2007-05-18 Cytovia, Inc. N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1970373A1 (en) 2005-12-02 2008-09-17 Mitsubishi Tanabe Pharma Corporation Alicyclic heterocyclic compound
KR20080085232A (ko) 2006-02-17 2008-09-23 화이자 리미티드 Tlr7 조절제로서 3-데아자퓨린 유도체
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2008009077A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
KR101507182B1 (ko) 2006-12-07 2015-03-30 제넨테크, 인크. 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
CA2672250C (en) 2006-12-20 2013-04-30 Ian Stansfield Antiviral indoles
CN101790380B (zh) 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
JP2008222557A (ja) 2007-03-08 2008-09-25 Kotobuki Seiyaku Kk ピロロ[3,2−d]ピリミジン誘導体及びこれを有効成分とする医薬組成物
ES2457316T3 (es) 2007-03-19 2014-04-25 Astrazeneca Ab Compuestos 8-oxo-adenina 9 sustituidos como moduladores del receptor similares a toll (TLR7)
PE20081887A1 (es) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
WO2008114819A1 (ja) 2007-03-20 2008-09-25 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
WO2008147697A1 (en) 2007-05-22 2008-12-04 Boehringer Ingelheim International Gmbh Benzimidazolone chymase inhibitors
CA2691444C (en) 2007-06-29 2016-06-14 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
JP2010535773A (ja) 2007-08-10 2010-11-25 グラクソスミスクライン エルエルシー ウイルス感染を治療するための窒素含有二環式化学物質
JP2010538004A (ja) 2007-08-28 2010-12-09 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としての2−ビフェニルアミノ−4−アミノピリミジン誘導体
WO2009030998A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Pyrimidine compounds as toll-like receptor (tlr) agonists
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
EP2238142B1 (en) 2007-12-24 2012-07-04 Janssen R&D Ireland Macrocyclic indoles as hepatitis c virus inhibitors
WO2009099650A2 (en) 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
JP2011518882A (ja) 2008-04-28 2011-06-30 メルク・シャープ・エンド・ドーム・コーポレイション Hcvns3プロテアーゼ阻害剤
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
UY31982A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
ES2438496T3 (es) 2008-08-01 2014-01-17 Ventirx Pharmaceuticals, Inc. Formulaciones de agonistas de receptores de tipo toll y su uso
EA201101650A1 (ru) 2009-05-21 2012-07-30 Астразенека Аб Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β-類澱粉生成之化合物
US20120232062A1 (en) 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
ES2644286T3 (es) 2009-10-22 2017-11-28 Gilead Sciences, Inc. Derivados de purina o deazapurina útiles para el tratamiento de (entre otros) infecciones víricas
KR101094446B1 (ko) 2009-11-19 2011-12-15 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노[3,2-d]피리미딘 화합물
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
US20120082658A1 (en) 2010-10-01 2012-04-05 Ventirx Pharmaceuticals, Inc. Methods for the Treatment of Allergic Diseases
WO2012066335A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012067269A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
SI3330257T1 (sl) * 2011-04-08 2020-07-31 Janssen Sciences Ireland Unlimited Company Derivati pirimidina za zdravljenje virusnih okužb
BR112013029537B1 (pt) 2011-05-18 2020-06-30 Janssen Sciences Ireland Uc derivados de quinazolina, seu uso no tratamento de infecções virais e outras doenças e composição farmacêutica que os compreende
ES2690082T3 (es) 2011-11-09 2018-11-19 Janssen Sciences Ireland Uc Derivados de purina para el tratamiento de infecciones virales
MX357296B (es) 2012-02-08 2018-07-03 Janssen Sciences Ireland Uc Derivados piperidinopirimidinicos para el tratamiento de infecciones viricas.
NZ700928A (en) 2012-04-24 2017-06-30 Vertex Pharma Dna-pk inhibitors
MX360718B (es) 2012-07-13 2018-11-13 Janssen Sciences Ireland Uc Purinas macrocíclicas para el tratamiento de infecciones víricas.
ES2707885T3 (es) 2012-08-10 2019-04-05 Janssen Sciences Ireland Unlimited Co Alquilpirimidinderivados para el tratamiento de infecciones víricas y otras enfermedades
EP2712866A1 (en) * 2012-10-01 2014-04-02 Centre National de la Recherche Scientifique (CNRS) 1,2,4-triazine derivatives for the treatment of viral infections
ES2701098T7 (es) * 2012-10-05 2021-02-03 Janssen Sciences Ireland Unlimited Co Derivados de acilaminopirimidina para el tratamiento de infecciones víricas y otras enfermedades
US9499549B2 (en) 2012-10-10 2016-11-22 Janssen Sciences Ireland Uc Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases
JP6297055B2 (ja) 2012-11-16 2018-03-20 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染症の治療のための複素環置換2−アミノ−キナゾリン誘導体
KR102300861B1 (ko) * 2013-02-21 2021-09-10 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
JP6336036B2 (ja) 2013-03-29 2018-06-06 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染治療のための大環状デアザプリノン
SG11201509520QA (en) 2013-05-24 2015-12-30 Janssen Sciences Ireland Uc Pyridone derivatives for the treatment of viral infections and further diseases
WO2014207082A1 (en) 2013-06-27 2014-12-31 Janssen R&D Ireland Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
MY179503A (en) 2013-07-30 2020-11-09 Janssen Sciences Ireland Uc Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
US9701661B2 (en) 2014-07-11 2017-07-11 Northwestern University 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase
JP7171444B2 (ja) 2016-07-01 2022-11-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー ウイルス感染治療用のジヒドロピラノピリミジン

Similar Documents

Publication Publication Date Title
JP2016530259A5 (ja)
JP2016503799A5 (ja)
JP2016121196A5 (ja)
JP2015537020A5 (ja)
JP2018507890A5 (ja)
JP2016518437A5 (ja)
JP2018530549A5 (ja)
JP2015514808A5 (ja)
JP2016540742A5 (ja)
JP2017509689A5 (ja)
JP2017508789A5 (ja)
JP2015508103A5 (ja)
JP2017514910A5 (ja)
JP2011037841A5 (ja)
JP2014508811A5 (ja)
JP2014501766A5 (ja)
JP2020097577A5 (ja)
JP2016503797A5 (ja)
JP2019524883A5 (ja)
JP2017517565A5 (ja)
JP2012513416A5 (ja)
JP2017501237A5 (ja)
JP2019526596A5 (ja)
JP2015512943A5 (ja)
JP2016531126A5 (ja)